Description

Pharmacokinetics:

Moxifloxacin, the active ingredient in Moxifloxacin as HCl formulations, exhibits excellent bioavailability and tissue penetration following oral or ocular administration. After absorption, Moxifloxacin reaches peak plasma concentrations within 1 to 4 hours, allowing for rapid onset of action. The drug is extensively distributed throughout the body, including tissues and fluids, where it exerts its antimicrobial effects. Moxifloxacin is primarily metabolized in the liver and eliminated via renal and non-renal routes, with a half-life of approximately 8 to 12 hours.

Pharmacodynamics:

Moxifloxacin belongs to the fluoroquinolone class of antibiotics, characterized by its bactericidal activity against a wide range of gram-positive and gram-negative bacteria. By inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, Moxifloxacin disrupts DNA replication, transcription, and repair processes, leading to cell death and eradication of susceptible pathogens. This mechanism of action confers Moxifloxacin with potent antimicrobial activity and makes it effective against various bacterial infections.

Drug Classification:

Moxifloxacin is classified as a fluoroquinolone antibiotic, indicated for the treatment of bacterial infections caused by susceptible organisms. It is available in multiple formulations, including eye drops and tablets, to address different types of infections and patient needs.

Formulations:

AIT Pharmaceuticals Division offers Moxifloxacin as HCl in the following formulations:

• Eye Drops: Each ml contains 5 mg of Moxifloxacin (as hydrochloride) in a sterile ophthalmic solution (0.5% w/v).
• Tablets: Each tablet contains 400 mg of Moxifloxacin (as hydrochloride) for oral administration.

Indications:

Moxifloxacin eye drops are indicated for the treatment of bacterial conjunctivitis and other ocular infections caused by susceptible organisms, including gram-positive and gram-negative bacteria. Moxifloxacin tablets are indicated for the treatment of various systemic infections, including respiratory tract infections, skin and soft tissue infections, and urinary tract infections, caused by susceptible bacteria.

Usage:

For ophthalmic use, instill one drop of Moxifloxacin eye drops into the affected eye(s) every 4 to 6 hours, or as directed by a healthcare professional. Avoid touching the dropper tip to any surface to prevent contamination. For oral use, swallow Moxifloxacin tablets whole with a full glass of water, with or without food, as directed by a healthcare provider. Do not crush, chew, or break the tablets.

Dosage:

The recommended dosage of Moxifloxacin eye drops and tablets may vary depending on the type and severity of the infection, as well as the patient’s age, weight, and renal function. Follow the dosage instructions provided by your healthcare provider for optimal therapeutic outcomes.

Side Effects:

Common side effects of Moxifloxacin may include mild ocular irritation, burning or stinging sensation, dry eyes, blurred vision, headache, dizziness, nausea, diarrhea, and abdominal pain. Rare but serious adverse reactions, such as allergic reactions, severe skin reactions, and tendon rupture, may occur. If you experience any unexpected or severe side effects, discontinue use of the medication and seek medical attention promptly.

Trust AIT Pharmaceuticals Division’s Moxifloxacin as HCl formulations to provide effective treatment for bacterial infections, whether ocular or systemic. With our commitment to quality and patient safety, we strive to deliver innovative healthcare solutions that empower individuals to lead healthier lives.